CN114149424B - 用于治疗疾病的杂环化合物 - Google Patents

用于治疗疾病的杂环化合物 Download PDF

Info

Publication number
CN114149424B
CN114149424B CN202111183182.7A CN202111183182A CN114149424B CN 114149424 B CN114149424 B CN 114149424B CN 202111183182 A CN202111183182 A CN 202111183182A CN 114149424 B CN114149424 B CN 114149424B
Authority
CN
China
Prior art keywords
optionally substituted
formula
compounds
another embodiment
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111183182.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114149424A (zh
Inventor
拉朱·莫汉
约翰·努斯
詹森·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oppilan Pharma Ltd USA
Original Assignee
Oppilan Pharma Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oppilan Pharma Ltd USA filed Critical Oppilan Pharma Ltd USA
Publication of CN114149424A publication Critical patent/CN114149424A/zh
Application granted granted Critical
Publication of CN114149424B publication Critical patent/CN114149424B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202111183182.7A 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物 Active CN114149424B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562255041P 2015-11-13 2015-11-13
US62/255,041 2015-11-13
PCT/US2016/061676 WO2017083756A1 (en) 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease
CN201680078856.8A CN108463222B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680078856.8A Division CN108463222B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物

Publications (2)

Publication Number Publication Date
CN114149424A CN114149424A (zh) 2022-03-08
CN114149424B true CN114149424B (zh) 2025-05-13

Family

ID=58696139

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680078856.8A Active CN108463222B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物
CN202111183182.7A Active CN114149424B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680078856.8A Active CN108463222B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物

Country Status (22)

Country Link
US (4) US10683291B2 (enExample)
EP (2) EP3373931B1 (enExample)
JP (3) JP6933384B2 (enExample)
KR (1) KR102720397B1 (enExample)
CN (2) CN108463222B (enExample)
AU (2) AU2016353348A1 (enExample)
BR (1) BR112018009745B1 (enExample)
CA (1) CA3005236C (enExample)
DK (1) DK3373931T3 (enExample)
ES (1) ES2932049T3 (enExample)
HR (1) HRP20221417T1 (enExample)
HU (1) HUE060594T2 (enExample)
IL (1) IL259297B2 (enExample)
LT (1) LT3373931T (enExample)
MX (1) MX382092B (enExample)
PL (1) PL3373931T3 (enExample)
PT (1) PT3373931T (enExample)
RS (1) RS63837B1 (enExample)
RU (1) RU2727194C2 (enExample)
SI (1) SI3373931T1 (enExample)
SM (1) SMT202300062T1 (enExample)
WO (1) WO2017083756A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221417T1 (hr) 2015-11-13 2023-02-03 Oppilan Pharma Ltd. Heterociklički spojevi za liječenje bolesti
EP3625230A1 (en) * 2017-05-17 2020-03-25 Oppilan Pharma Ltd. Prodrugs for the treatment of disease
WO2018211323A1 (en) * 2017-05-17 2018-11-22 Oppilan Pharma Ltd. Hetercyclic compounds for the treatment of disease
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds
US20240010649A1 (en) 2022-07-06 2024-01-11 Oppilan Pharma Limited Crystalline forms of an s1p receptor modulator
WO2024151993A1 (en) * 2023-01-13 2024-07-18 Oppilan Pharma Limited Preparation of an s1p receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772597A (en) * 1983-10-14 1988-09-20 Pfizer Inc. 2-azacycloalkylthiopenem derivatives
AU2004277947A1 (en) 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
RU2425832C2 (ru) * 2006-04-03 2011-08-10 Астеллас Фарма Инк. Гетеросоединение
JP2010513283A (ja) 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
WO2010065760A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
US20100249071A1 (en) 2009-03-30 2010-09-30 Exelixis, Inc. Modulators of S1P and Methods of Making And Using
US9011494B2 (en) 2009-09-24 2015-04-21 Warsaw Orthopedic, Inc. Composite vertebral rod system and methods of use
ES2665461T3 (es) 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
CN103124727B (zh) * 2010-07-20 2015-03-25 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物
BR112014009348A2 (pt) 2011-10-20 2017-04-18 Glaxosmithkline Llc aza-heterociclos substituídos bicíclicos e análogos como moduladores de sirtuina
CR20160296A (es) * 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
HRP20221417T1 (hr) 2015-11-13 2023-02-03 Oppilan Pharma Ltd. Heterociklički spojevi za liječenje bolesti

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RN:97899-35-9;ACS;《STN Registry》 *

Also Published As

Publication number Publication date
JP2021191753A (ja) 2021-12-16
US20230339944A1 (en) 2023-10-26
BR112018009745A8 (pt) 2019-02-26
CA3005236A1 (en) 2017-05-18
RU2727194C2 (ru) 2020-07-21
HRP20221417T1 (hr) 2023-02-03
EP3373931A1 (en) 2018-09-19
AU2021202945A1 (en) 2021-06-03
AU2016353348A1 (en) 2018-07-05
PL3373931T3 (pl) 2023-02-06
SMT202300062T1 (it) 2023-03-17
EP4163281A1 (en) 2023-04-12
JP2023017862A (ja) 2023-02-07
IL259297A (en) 2018-07-31
LT3373931T (lt) 2023-03-10
RS63837B1 (sr) 2023-01-31
DK3373931T3 (da) 2022-11-28
US20200325135A1 (en) 2020-10-15
CN114149424A (zh) 2022-03-08
EP3373931B1 (en) 2022-09-28
CN108463222A (zh) 2018-08-28
RU2018121416A3 (enExample) 2019-12-17
US10683291B2 (en) 2020-06-16
WO2017083756A1 (en) 2017-05-18
JP6933384B2 (ja) 2021-09-08
BR112018009745B1 (pt) 2023-09-26
BR112018009745A2 (pt) 2018-11-06
JP2018535261A (ja) 2018-11-29
MX382092B (es) 2025-03-04
IL259297B (en) 2022-11-01
CA3005236C (en) 2024-02-20
SI3373931T1 (sl) 2023-02-28
KR20180095811A (ko) 2018-08-28
CN108463222B (zh) 2021-10-22
ES2932049T3 (es) 2023-01-09
KR102720397B1 (ko) 2024-10-21
PT3373931T (pt) 2022-12-06
AU2021202945B2 (en) 2022-06-23
MX2018005987A (es) 2018-11-29
JP7174963B2 (ja) 2022-11-18
US20190241556A1 (en) 2019-08-08
EP3373931A4 (en) 2019-04-03
US20220227767A1 (en) 2022-07-21
JP7445325B2 (ja) 2024-03-07
RU2018121416A (ru) 2019-12-13
IL259297B2 (en) 2023-03-01
HUE060594T2 (hu) 2023-03-28

Similar Documents

Publication Publication Date Title
CN114008033B (zh) 胰高血糖素样肽1受体激动剂
CN114149424B (zh) 用于治疗疾病的杂环化合物
US10590079B2 (en) Cyano-substituted indoles as LSD1 inhibitors
CN104945401B (zh) Ip化合物及它们在治疗中的应用
AU2014400628A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
TW201206944A (en) Morpholine compounds
US20150152083A1 (en) Compounds and Compositions for Modulating EGFR Activity
KR20230175222A (ko) Nek7 억제제
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
JP2024510935A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
EP3625230A1 (en) Prodrugs for the treatment of disease
WO2018211323A1 (en) Hetercyclic compounds for the treatment of disease
WO2024077057A1 (en) Phenyl oxy amide kinase inhibitors
HK40070316A (en) Heterocyclic compounds for the treatment of disease
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease
HK1260375B (zh) 用於治疗疾病的杂环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40070316

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant